Discover how arbovirus E Dimer vaccines are engineered to improve safety by minimizing antibody dependent enhancement.
India’s first dengue vaccine, Qdenga, offers protection against all four strains, reducing severe illness risk. Experts say ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial ...
Please provide your email address to receive an email when new articles are posted on . Qdenga offered protection against all four dengue serotypes for 7 years, Takeda said. The vaccine is not ...
Dengue fever caused by a flavivirus DENV is a global health threat, putting millions of people at risk. Several dengue vaccines have been designed in the past but significant challenges like ADE exist ...
MOBILIZE-1 is the first Phase 3 study being initiated for V181 as part of a planned robust clinical development program Study will evaluate a single dose of V181 for the prevention of dengue disease ...
Expert Rev Vaccines. 2013;12(9):995-1010. Based on the promising preclinical data, a monovalent recombinant DEN-80E protein has been tested in Phase I studies in flavivirus-naïve healthy volunteers.
Newspoint on MSN
Dengue vaccine India: The first dengue vaccine in India gets the green signal, know who will get this dose and how?
Dengue Symptoms and Treatment: The country has received its first dengue vaccine. This step is considered a major step ...
“Dengue can affect anyone living in or traveling to endemic areas - regardless of age, health and socio-economic circumstances,” said Gary Dubin, president of Takeda’s Vaccine Business Unit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results